Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:59PM ET
264.10
Dollar change
+5.29
Percentage change
2.04
%
IndexRUT P/E- EPS (ttm)-19.94 Insider Own18.78% Shs Outstand19.88M Perf Week3.46%
Market Cap5.26B Forward P/E- EPS next Y-14.14 Insider Trans12.22% Shs Float16.16M Perf Month3.88%
Income-373.63M PEG- EPS next Q-6.23 Inst Own93.67% Short Float20.18% Perf Quarter11.55%
Sales0.00M P/S- EPS this Y-16.32% Inst Trans-1.70% Short Ratio5.80 Perf Half Y74.35%
Book/sh20.39 P/B12.95 EPS next Y39.20% ROA-74.49% Short Interest3.26M Perf Year9.68%
Cash/sh31.87 P/C8.29 EPS next 5Y0.00% ROE-123.98% 52W Range119.76 - 322.67 Perf YTD14.14%
Dividend Est.- P/FCF- EPS past 5Y-55.24% ROI-71.58% 52W High-18.15% Beta-0.47
Dividend TTM- Quick Ratio5.38 Sales past 5Y0.00% Gross Margin- 52W Low120.52% ATR (14)17.18
Dividend Ex-Date- Current Ratio5.38 EPS Y/Y TTM-15.71% Oper. Margin0.00% RSI (14)55.74 Volatility5.11% 6.67%
Employees376 Debt/Eq0.29 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price394.54
Option/ShortYes / Yes LT Debt/Eq0.29 EPS Q/Q-13.93% Payout- Rel Volume0.46 Prev Close258.81
Sales Surprise- EPS Surprise-8.42% Sales Q/Q- EarningsFeb 28 BMO Avg Volume562.63K Price264.10
SMA203.13% SMA5011.88% SMA20030.88% Trades Volume143,552 Change2.04%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Upgrade B. Riley Securities Sell → Neutral $155 → $270
Mar-06-24Initiated Citigroup Buy $382
Feb-26-24Downgrade B. Riley Securities Neutral → Sell $155
Dec-20-22Reiterated Oppenheimer Outperform $170 → $250
Dec-19-22Upgrade Raymond James Underperform → Mkt Perform
Dec-19-22Reiterated Piper Sandler Overweight $203 → $280
Dec-19-22Reiterated H.C. Wainwright Buy $170 → $225
Jul-08-22Downgrade B. Riley Securities Buy → Neutral $131 → $75
Oct-07-21Initiated Jefferies Buy $151
Aug-06-21Upgrade BMO Capital Markets Market Perform → Outperform
Mar-26-24 09:53AM
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM
04:47PM Loading…
04:47PM
04:12PM
04:04PM
03:15PM
07:00AM
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
03:50PM
02:34PM Loading…
02:34PM
01:45PM
12:56PM
12:09PM
10:17AM
10:01AM
09:30AM
07:45AM
05:35AM
Mar-14-24 04:25PM
04:15PM
12:11PM
Mar-09-24 05:52AM
Mar-06-24 04:05PM
Mar-05-24 08:00AM
06:03AM Loading…
06:03AM
Feb-28-24 07:01AM
07:00AM
06:45AM
Feb-26-24 04:04PM
10:52AM
Feb-23-24 05:43AM
Feb-21-24 08:00AM
Feb-13-24 01:36PM
Feb-08-24 08:00AM
Feb-06-24 04:05PM
11:29AM
11:28AM
Jan-29-24 08:00AM
02:59AM
Jan-22-24 08:00AM
01:29AM
Jan-04-24 08:00AM
01:21AM
Jan-03-24 04:30PM
Dec-30-23 06:50AM
Dec-22-23 04:30PM
Dec-19-23 01:02PM
10:16AM
Dec-15-23 11:01PM
Dec-07-23 08:45AM
Nov-27-23 04:30PM
09:50AM
Nov-24-23 10:00AM
Nov-21-23 08:00AM
Nov-17-23 10:46AM
Nov-16-23 03:03PM
Nov-15-23 04:45PM
Nov-14-23 10:56AM
Nov-13-23 04:40PM
Nov-10-23 08:00AM
07:30AM
Nov-07-23 04:54AM
Nov-06-23 08:00AM
06:29AM
Nov-04-23 12:16PM
Nov-02-23 04:05PM
Oct-27-23 10:01AM
Oct-17-23 09:53AM
Oct-12-23 04:05PM
07:49AM
Oct-02-23 11:51AM
Sep-29-23 12:41PM
Sep-28-23 10:30PM
04:01PM
Sep-27-23 09:53AM
Sep-25-23 08:08PM
Sep-21-23 09:25AM
09:25AM
01:00AM
Sep-20-23 07:00AM
Sep-14-23 04:30PM
Sep-13-23 04:10PM
09:10AM
Sep-11-23 07:00AM
Sep-09-23 03:59PM
Sep-04-23 03:43PM
Aug-30-23 08:54AM
Aug-23-23 06:40AM
Aug-14-23 07:02PM
Aug-08-23 08:50AM
08:00AM
Jul-17-23 08:00AM
Jul-10-23 09:32AM
09:29AM
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Sale238.502,000477,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 14 '23Buy228.3220,6334,710,8931,793,403Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Sale232.502,000465,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Option Exercise87.922,500219,8008,167Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 13 '23Buy219.3981,15917,805,6841,774,294Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Sale225.402,500563,5005,667Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Option Exercise87.921,300114,2966,967Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 12 '23Buy218.3134,5787,548,6161,699,129Dec 14 06:09 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Sale217.851,300283,2005,667Dec 14 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Option Exercise87.091,00087,09016,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Sale227.331,000227,33015,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Option Exercise81.161,800146,09016,801Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Sale218.871,800393,96415,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Option Exercise73.753,000221,25018,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Sale204.583,000613,73015,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Option Exercise73.754,000295,00019,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Sale199.194,000796,75015,001Dec 01 04:30 PM
BAKER BROS. ADVISORS LPDirectorNov 21 '23Buy188.4764,35012,128,3401,667,104Nov 21 06:15 PM
BAKER BROS. ADVISORS LPDirectorNov 20 '23Buy185.7420,7093,846,5751,607,668Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 17 '23Buy174.7046,3708,100,7041,588,541Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 15 '23Buy161.9715,1992,461,7211,545,775Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy154.0037,6605,799,6531,500,227Nov 15 05:12 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy156.4234,1885,347,8371,531,757Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 13 '23Buy143.2169,83910,001,3681,465,494Nov 15 05:12 PM